TY  -  
T1  - Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia 
SN  -  /  
UR  - http://hdl.handle.net/10138/237301 
T3  -  
A1  - Koskela, Hanna L. M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Bruemmendorf, Tim H.; Gjertsen, Bjorn T.; Janssen, Jeroen; Lotfi, Kourosh; Markevarn, Berit; Olsson-Stromberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu 
A2  -  
PB  -  
Y1  - 2017 
LA  - eng 
AB  - Purpose Tyrosine kinase inhibitors (TKIs) have well-characterized immunomodulatory effects on T and NK cells, but the effects on the humoral immunity are less well known. In this project, we studied TKI-induced changes in B cell-mediated immunity. Methods We collected peripheral blood (PB) and bone marrow (BM) samples from chronic myeloid leukemia (CML) patients before and during first-line imatinib (n = 20), dasatinib (n = 16), nilotinib (n = 8), and bosutinib (n = 12) treatment. Plasma immunog... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - CML; Tyrosine kinase inhibitor; B cell; Immunoglobulin; PATIENTS RECEIVING IMATINIB; CHRONIC-PHASE; PHILADELPHIA-CHROMOSOME; BONE-MARROW; FOLLOW-UP; DASATINIB; NILOTINIB; ANTIGEN; HYPOGAMMAGLOBULINEMIA; COMBINATION; 3122 Cancers 
N1  -   
PP  -  
ER  -